FY27 revenue growth of at least 15%
Management guided a minimum 15% topline growth for FY27, with potential upside to 20% if positive factors materialize.
GUFICBIOSCIENCES / guidance tracker
Keep management guidance in view.
Gufic Biosciences · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin to improve to 19% by FY28
As Indore utilization exceeds 50%, EBITDA margin expected to rise from current 16% to 19%, and to 20-21% at >75% utilization.
Indore EU GMP certificate by March-April 2026
EU audit completed in December 2025; certificate expected by March or April, enabling regulated market exports from Q4/Q1.
Filler product launch by June-July 2026
Licensing deal with a Canadian company for dermal fillers; product launch expected in June-July to complement botox portfolio.